Translational research in lung cancer

Seminars in Surgical Oncology

Volumn 21, Issue 3, 2003, Pages 205-219

  Chen, Yuhchyau ^a,b   Okunieff, Paul ^a   Ahrendt, Steven A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Box 647 ^*  (United States)

Author keywords

Chemoradiation; Cytokine; Molecular screening; Non small cell lung cancer; Targeted therapy

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 7 HYDROXYSTAUROSPORINE; ANGIOSTATIN; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ENDOSTATIN; ERLOTINIB; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GEMCITABINE; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; IRINOTECAN; ISIS 3521; LONAFARNIB; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; NAVELBINE; PACLITAXEL; PANITUMUMAB; PRINOMASTAT; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; REBIMASTAT; SEMAXANIB; TANOMASTAT; TIPIFARNIB; TIRAPAZAMINE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN ANTIBODY;

ADVANCED CANCER; ANEMIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER LOCALIZATION; CLINICAL RESEARCH; CYTOKINE PRODUCTION; DISEASE MARKER; DRUG INDUCED DISEASE; EARLY DIAGNOSIS; ESOPHAGITIS; FATIGUE; GENETIC SCREENING; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; MUCOSA INFLAMMATION; NAUSEA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RADIATION PNEUMONIA; RADIOSENSITIVITY; REVIEW; RISK ASSESSMENT; TARGET CELL; TECHNOLOGY; TRANSLATION REGULATION; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; LUNG NEOPLASMS; PACLITAXEL; PROGNOSIS; RADIATION PNEUMONITIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0141885210     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/ssu.10039     Document Type: Review

References (73)

1. "Cancer Facts and Figures 2002." Atlanta, GA: American Cancer Society; 2002.
2. Naruke T, Goya T, Tsuchiya R, Suemasu K: Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988;96:440-447.
3. Sidransky D: Molecular markers in cancer diagnosis. J Natl Cancer Inst Monogr 1995;17:27-29.
4. Sidransky D: Nucleic acid-based methods for the detection of cancer. Science 1997;278(5340):1054-1059.
5. Ahrendt SA, Sidransky D: The potential of molecular screening. Surg Oncol Clin N Am 1999;8:641-656.
6. Berlin NI, Buncher CR, Fontana RS, et al: The National Cancer Institute Cooperative Early Lung Cancer Detection Program. Results of the initial screen (prevalence). Early lung cancer detection: introduction. Am Rev Respir Dis 1984;130:545-549.
7. Strauss GM, Gleason RE, Sugarbaker DJ: Screening for lung cancer. Another look; a different view. Chest 1997;111:754-768.
8. Mao L, Hruban RH, Boyle JO, et al: Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994;54:1634-1637.
9. Palmisano WA, Divine KK, Saccomanno G, et al: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-5958.
10. Mills NE, Fishman CL, Scholes J, et al: Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J Natl Cancer Inst 1995;87:1056-1060.
11. Ahrendt SA, Chow JT, Xu LH, et al: Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999;91:332-339.
12. Fliss MS, Usadel H, Caballero OL, et al: Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000;287(5460):2017-2019.
13. Esteller M, Sanchez-Cespedes M, et al: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
14. Sozzi G, Conte D, Mariani L, et al: Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001;61:4675-4678.
15. Usadel H, Brabender J, Danenberg KD, et al: Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002;62:371-375.
16. Bearzatto A, Conte D, Frattini M, et al: p16(INK4A) hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res 2002;8:3782-3787.
17. Ahrendt SA, Decker PA, Alawi EA, et al: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001;92:1525-1530.
18. Ahrendt SA, Chow JT, Yang SC, et al: Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Cancer Res 2000;60:3155-3159.
19. Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA: DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002;21:5450-5461.
20. Sanchez-Cespedes M, Parrella P, Nomoto S, et al: Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2001;61:7015-7019.
21. Brundage MD, Davies D, Mackillop WJ: Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-1057.
22. Nelson HH, Christiani DC, Mark EJ, et al: Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999;91:2032-2038.
23. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055-4063.
24. Hu YC, Casse C, Benoit N, et al: p53 gene mutations predict poor survival in stage I non-small cell lung cancer: results of a prospective trial. Proc Am Assoc Cancer Res 2002;43:8-32.
25. Tomizawa Y, Kohno T, Kondo H, et al: Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage 1 lung adenocarcinoma. Clin Cancer Res 2002;8:2362-2368.
26. Tang X, Khuri FR, Lee JJ, et al: Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1511-1516.
27. Bhattacharjee A, Richards WG, Staunton J, et al: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-13795.
28. Garber ME, Troyanskaya OG, Schluens K, et al: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001;98:13784-13789.
29. Beer DG, Kardia SL, Huang CC, et al: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-824.
30. Wigle DA, Jurisica I, Radulovich N, et al: Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 2002;62:3005-3008.
31. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992;326:524-530.
32. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:26-92.
33. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990;323:940-945.
34. Arriagada R, le Chevalier T, Quoix E, et al: ASTRO Plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phy 1991;20;1183-1190.
35. Sause W, Kolesar P, Taylor S IV, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-364.
36. Curran WJ Jr, Scott C, Langer C, et al: Phase III comparison of sequential vs. concurrent chemoradiation for PTS with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2000;19:484a:1891.
37. Tishler RB, Geard CR, Hall EJ, Schiff PB: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992;52:3495-3497.
38. Geard CR, Jones JM, Schiff PB: Taxol and radiation. J Natl Cancer Inst Monogr 1993;15:89-94.
39. Choy H, Yee L, Cole BF: Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation. Semin Oncol 1995;22:38-44.
40. Lau D, Ryu J, Gandara D, et al: Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer. Semin Radiat Oncol 1999;9:117-120.
41. Rosenthal DI, Okani O, Corak J, et al: Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study. Semin Oncol 1997;24S:12096-12100.
42. Kirkbride P, Gelmon K, Eisenhauer E: Paclitaxel and concurrent radiotherapy in locally advanced non-small cell lung cancer: the Canadian experience. Semin Radiat Oncol 1999;9:102-107.
43. Aisner J, Belani CP, Kearns C, et al: Feasibility and pharmacokinetic of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and fro regionally advanced non-small cell lung cancer. Semin Oncol 1995;22:17-21.
44. Havemann K, Wolf M, George C, et al: Paclitaxel and simultaneous radiation in the treatment of stage III A/B non-small cell lung cancer. Semin Oncol 1995;22:19-22.
45. Antonia SJ, Wagner H, Williams C, et al: Concurrent paclitaxel/ cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung. Semin Oncol 1995;22:34-37.
46. Greco FA, Stroup SL, Gray JR, Hainsworth JD: Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Clin Oncol 1996;14:1642-1648.
47. Chen Y, Pandya K, Keng PC, et al: Phase I/II clinical study of pulsed paclitaxel radiosensitization for thoracic malignancy: a therapeutic approach on the basis pre-clinical research of human cancer cell lines. Clin Cancer Res 2003;9:969-975.
48. Morton RF, Jett JR, McGinnis WL, et al: Thoracic radiation therapy alone compared with combined chemotherapy for locally unresectable non-small cell lung cancer. Ann Int Med 1991;115:681-686.
49. Chen Y, Pandya K, Keng P, et al: Pharmacokinetic of low-dose paclitaxel: toxicity of phase I study and implication for radiosensitization for non-small cell lung cancer [Abstract]. Proc Am Soc Clin Oncol 2002;21:120a:477.
50. Movsas B, Scott C, Curran W, et al: A quality adjusted time without symptoms or toxicity (QTWIST) analysis of Radiation Therapy Oncology Group (RTOG) 94-10 [Abstract]. Proc Am Soc Clin Oncol 2001;20:313a:1247.
51. Rubin P, Johnston CJ, Williams JP, et al: A perpetual cascade of cytokines post-irradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 1995;33:99-109.
52. Johnston CJ, Wright TW, Rubin P, Finkelstein JN: Alterations in the expression of chemokine mRNA levels in fibrosis-resistant and -sensitive mice after thoracic irradiation. Exp Lung Res 1998;24:321-337.
53. Anscher MS, Kong FM, Andrews K, et al: Plasma transforming growth factor β1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998;41:1029-1035.
54. Chen Y, Rubin P, Williams J, et al: Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 2001;49:641-648.
55. Chen Y, Williams J, Ding I, et al: Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 2002;12:26-33.
56. Stevens CW, Lee JS, Cox J, Komaki R: Novel approaches to locally advanced unresectable non-small cell lung cancer. Radiother Oncol 2000;55:11-18.
57. Schiller JH, Harrington D, Belani CP, et al: The Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-98.
58. Raben D, Helfrich BA, Chan D, et al: ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 2002;29(Suppl 4):37-46.
59. Browder T, Butterfield CE, Kraling BM, et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
60. Boehm T, Folkman J, Browder T, O'Reilly MS.: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390(6658):404-407.
61. Swisher SG, Roth JA, Nemunaitis J, et al: Adenovirus mediated p53 gene transfer in advanced non-small cell lung cancer. J Natl Cancer Inst 1999;91:763-771.
62. Nemunaitis J, Swisher SG, Timmons T, et al: Adenovirus mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. J Clin Oncol 2000;18:609-622.
63. Schuler M, Herrmann R, De Greve JL, et al: Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001;19:1750-1758.
64. Fukuoka M, Yano S, Giaccone G, et al: Final results from a phase II trial of ZD1839 ('Iressa') [Abstract]. Proc Am Soc Clin Oncol 2002;21:298a: 1188.
65. Kris MG, Natale RB, Herbst RS, et al: A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum and docetaxel based regiments (IDEAL 2) [Abstract]. Proc Am Soc Clin Oncol 2002;21:292a: 1166.
66. Douillard J-Y, Giaccone G, Horai T, et al: Improvement in disease-related symptoms and quality of life in patients with advanced non-small cell lung cancer (NSCLC) treated with ZD 1839 ('Iressa') (IEDAL 1) [Abstract]. Proc Am Soc Clin Oncol 2002;21:299a:1195.
67. Natale RB, Skarin A, Maddox A-M, et al: Improvement in symptoms and quality of life for advanced non-small cell lung cancer patients receiving ZDX1839 ('Iressa') in IDEAL 2 [Abstract]. Proc Am Soc Clin Oncol 2002;21:292a: 1167.
68. Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999;103:1237-1241.
69. Drummond AH, Beckett P, Brown PD, et al: Preclinical and clinical studies of MMP inhibitors in cancer. Ann NY Acad Sci 1999;878:228-235.
70. Smylie M, Mercier R, Aboulafia D, et al: Phase III study of the matrix metalloproteinase (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer [Abstract]. Proc Am Soc Clin Oncol 2001;20:307a:1226.
71. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
72. DeVore RF, Fehrenbacher L, Herbst RS, et al: A randomized phase II trial comparing rhuMAbVEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC [Abstract]. Proc Am Soc Clin Oncol 2000;19:485a:1896.
73. Johnson DH, DeVore F, Kabbinavar R, et al: Carboplatin (C) + paclitaxel (T) + rhuMAb-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer [Abstract]. Proc Am Soc Clin Oncol 2001;20:315a:1256.